Company: APM
Filing Date: 2025-07-22
Form Type: 6-K
Source: 0001213900-25-066642
Chunk: 1

Company: Aptorum Group Ltd
Filing Date: 2025-07-22
Form: 6-K
Chunk 1
---
 into an intellectual property license agreement (“Licensing Agreement”), pursuant to which
DiamiR and DiamiR LLC shall license on a non-exclusive basis their respective intellectual properties to Aptorum Therapeutics in exchange
for upfront and periodic payments and royalties until the earlier of the closing of the Merger or December 31, 2025.

Immediately prior to the closing of the Merger, Aptorum will transfer
by way of continuation to and domesticate as a Delaware corporation (the “Domestication”; the Company immediately following
the Domestication and prior to the closing of Merger, “Aptorum Delaware”). In connection with the Domestication, each then
issued and outstanding Class A ordinary share of Aptorum will convert automatically, on a one-for-one basis, into a share of common
stock of Aptorum Delaware, and each then issued and outstanding Class B ordinary share of Aptorum will convert automatically into
a share of common stock of Aptorum Delaware and a share of non-voting and non-convertible Series A preferred stock of Aptorum Delaware.

At the effective time of the
Merger (the “Effective Time”), each then-outstanding share of DiamiR’s common stock, other than dissenting shares, will
be converted into a number of shares of Aptorum Delaware common stock equal to the Conversion Ratio described in more detail in the section
titled “The Merger Agreement-Conversion Ratio” (the “Conversion Ratio”). Immediately following the closing of
the Merger, stockholders of DiamiR and existing Aptorum shareholders will own approximately 70% and 30%, respectively, of the outstanding
shares of the Combined Company.

About DiamiR

DiamiR was incorporated in Delaware on June 16, 2014, and primarily
operates through its wholly owned subsidiary, DiamiR, LLC, which was incorporated as a limited liability company in Delaware on September 17,
2009. DiamiR is a molecular diagnostics company focused on developing and commercializing minimally invasive tests for early detection
and monitoring of neurodegenerative diseases, such as mild cognitive impairment and Alzheimer’s disease, rare neurodevelopmental
diseases, such as Rett syndrome, other brain health disorders, and cancer. The proprietary platform technology developed at DiamiR and
protected by over 50 issued patents is based on quantitative analysis of organ-enriched microRNAs detectable in blood plasma. In addition
to blood-based microRNA panels, as part of its biopharma